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Peanut Allergy: An Overview
Nasser Al-  Ahmed, MD, Shirina Alsowaidi, MD, and Peter Vadas, MD, PhD
Peanut allergies have been increasing in prevalence in most industrialized countries. Onset is typically in early childhood, with a trend towards earlier 
ages of presentation. the allergy is lifelong in most affected children, although 15–22% will outgrow their peanut allergy, usually before their teenage 
years. Manifestations of peanut allergy range from mild to severe, and risk factors predisposing to severe reactions are discussed. However, even in 
the absence of risk factors, peanut allergic individuals may still experience life-  threatening anaphylactic reactions. approaches to investigation and 
treatment, patterns of   cross-  reactivity and possible causes of rising prevalence are discussed.
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challenges, the total estimate for clinical peanut allergy was 
1.5% of 3-   to 4-  year-  old children.10 The results from those two 
studies are suggestive of an overall increase in the prevalence 
of peanut allergy among children. Another study estimated 
the prevalence of peanut allergy to be 1.34% among primary 
school children in a Canadian province.11
Clinical Reactions to Peanuts
Allergies to peanut have a spectrum of clinical presentations 
ranging from cutaneous manifestations to life-  threatening sys-
temic reactions. Symptoms usually develop within minutes af-
ter ingestion of even a trace amount of peanut and may involve 
cutaneous, cardiovascular, gastrointestinal, genitourinary, 
and / or respiratory systems. Progressive upper or lower respi-
ratory symptoms, hypotension, and arrhythmias typically de-
velop in fatal and near-  fatal cases.12 Factors that appear to 
contribute to a fatal outcome include a concomitant diagnosis 
of asthma, a delay in the administration of epinephrine, pre-
vious severe allergic reactions to peanut, and not recognizing 
the presence of peanut in the meal. Initial reactions occur at 
the first apparent exposure in 72% of patients, with a median 
age of 24 months, and most reactions occur in the home.13 
In this study, 89% of initial reactions involved the skin, 52% 
the respiratory tract, and 34% the gastrointestinal tract. Two 
organ systems were affected in 31% of reactions, and all three 
systems were affected in 21%. Moreover, subsequent acciden-
tal reactions occurred in 55% of   peanut-  allergic patients over a 
median period of 5.5 years with similar symptoms. This illus-
trates the difficulty of strict avoidance of this ubiquitous food 
product even in those patients compliant with the recommen-
dations made by treating physicians. Patients with isolated 
cutaneous manifestations had lower serum   peanut-  specific 
IgE levels than the group with respiratory and / or gastro-
intestinal symptoms, with a median of 1.25 kUA /   L versus 
11.65 kUA /   L.14 However, despite this, there was no threshold   
level below which only skin manifestations appeared to occur.
F
ood allergy is a common problem encountered by pri-
mary care physicians. It is estimated to affect 4 to 8% of 
children and 1 to 2% of adults and is considered a major cause 
of life-  threatening hypersensitivity reactions.1–3 Eight foods are 
responsible for more than 90% of food allergies: cow’s milk, 
egg, soy, wheat, peanut, tree nuts, fish, and shellfish.4 Among 
those foods, peanut has attracted considerable attention for 
several reasons. Peanut allergy is common, typically with on-
set in the first few years of life. Allergy to peanut usually is 
lifelong and accounts for most of the food-  induced severe and 
fatal allergic reactions.5 Hence, the diagnosis of peanut allergy   
carries with it considerable medical and emotional significance.6
Prevalence
The prevalence of anaphylaxis from all causes is rising, but 
food-  induced anaphylaxis is causing a disproportionate in-
crease in the rates of anaphylaxis.7 A recent study in the 
United States assessed the prevalence of peanut allergy by 
random telephone survey. The prevalence of peanut allergy 
was estimated to affect 0.8% of children and 0.6% of adults,8 
showing a twofold increase over a 5-  year period.9 In the Isle 
of Wight, United Kingdom, a study was conducted on a birth 
cohort of 3-   and 4-  year-  old children born between 1994 and 
1996, and the results were compared with those of a cohort 
born in 1989. There was a documented twofold increase in 
reported peanut allergy (0.5–1.0%) and a threefold increase 
in sensitization, and after further analysis that included oral 
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Cosensitization to tree nuts is also common, although 
the   cross-  reacting proteins are not yet known. The rate of co-
allergy varies from 2.5% in one survey9 to as high as approxi-
mately one-  third of   peanut-  allergic patients.13 There is a high 
degree of cosensitization with seeds.23
Theories on Why the Prevalence of Peanut Allergy 
Is Increasing
It remains unclear why the prevalence of peanut allergy is ris-
ing in the Western world. Multiple theories have tried to ex-
plain the overall increase in the prevalence of allergic diseases 
in the Western world over the last decade, mainly describing 
an imbalance between the T-  helper 1 (Th1) /   T-  helper 2 (Th2)-
  biased cellular responses in early life.24 Other theories have 
been advanced to explain the rise of peanut allergy. The ma-
jor peanut allergens have been detected in the breast milk of 
lactating women.25 This occult exposure through breast milk 
from mothers ingesting peanut during lactation may sensitize 
the infants to peanut and thus explain the occurrence of al-
lergic reactions to peanut on first exposure in the majority of 
children.13 Alternatively, exposure of infants to peanut protein 
via breast milk in the perinatal period may aid in the develop-
ment of immunologic tolerance in some infants.
The methods by which peanuts are prepared may contrib-
ute to the increase prevalence of peanut allergy in the West-
ern hemisphere. Peanuts are prepared mainly by dry roasting, 
including peanuts that are made into peanut butter. Roasting 
has been shown to alter both the structure and the allergenic-
ity of peanut.26 Dry roasting also induces functional altera-
tions by causing a 3.6-  fold increase in the function of Ara h2, 
which acts as a trypsin inhibitor protecting Ara h1 from pro-
teolytic digestion.26 Lack and colleagues found an association 
between peanut allergy in   preschool-  age children and a family 
history of peanut allergy, consumption of soy during infancy, 
early onset of eczema, other rashes with oozing and crust-
ing, and exposure to topical preparations containing peanut 
oil.27 The latter are present in the form of emollients for the 
treatment of diaper rash, eczema, dry skin, and inflammatory 
cutaneous conditions during infancy.
Other Names and Common Sources of Hidden 
Peanut Products
Warnings and educational brochures about allergy to pea-
nuts are distributed by the Canadian Food Inspection Agency 
(<http: //   www  .inspection.gc  .ca>). Peanuts may be manufac-
tured under other names, including arachis oil, beer nuts, 
cacahouette, goober nuts or peas, ground nuts, mandelonas, 
nu-  nuts, nut meats, and valencias.24
Possible hidden sources of peanut exposure include almond 
Diagnosis
The evaluation of a child with suspected allergy to peanut 
should include a careful history taking, skin-  prick testing, 
measurement of   serum-  specific IgE, and, possibly, an oral 
food challenge.12 The use of ImmunoCAP, a serologic test, 
can be both diagnostic and prognostic as a   peanut-  specific 
serum IgE level of 15 kUA /   L or higher has a 95% predictive 
value for an allergic reaction on ingestion of peanut.15 Patients 
developing typical allergic symptoms after the isolated inges-
tion of peanut protein who have evidence of   peanut-  specific 
IgE antibodies, that is, by a positive skin-  prick test and / or 
ImmunoCAP, do not need to undergo a confirmatory oral   
challenge.
Skin testing is generally relied on for diagnosis. A wheal 
3 mm greater than the negative control is considered a posi-
tive reaction.16 Overall, a negative skin-  prick test to peanut 
has a negative predictive value of more than 95%.15 The posi-
tive predictive value, however, is significantly lower, reaching 
only 60% in patients with a convincing history of an allergic 
reaction.17 A recent study showed that a positive skin-  prick 
test with a wheal diameter of 8 mm or more had a predictive 
value of 95% (95% confidence interval 76.2–99.9) for a posi-
tive challenge.18
For acute allergic reactions, the diagnosis is based on clin-
ical symptoms, a history of exposure to relevant allergen, and 
supportive skin-  prick tests and / or ImmunoCAP test. Serum 
β-  tryptase level, considered the hallmark of mast cell activa-
tion, may not be helpful since it can be normal in patients with 
food-  induced anaphylaxis.19
The three major allergenic proteins in peanut are Ara h1, 
h2, and h3.20
Cross-  Reactivity with Other Foods
Peanut belongs to the plant family Leguminosae. The legume 
family also includes soybeans, peas, lima beans, green beans, 
other beans, chickpeas, and lentils. The fact that they are low 
in fat, contain no cholesterol, and are high in protein, folate, 
potassium, iron, and magnesium has contributed to their 
widespread consumption in the North American diet.
Barnett and colleagues demonstrated a high rate of   cross-   
reactivity between peanut and legumes when they screened 
sera from 40 patients with peanut allergy against 10 other 
legumes.21 There was demonstrable IgE binding to multiple 
  legumes in 38% of patients. However, clinical   cross-  reactions 
are uncommon. In a study of 32 children with peanut allergy 
confirmed by a   double-  blinded,   placebo-  controlled oral food 
challenge, 10 (31%) had a positive skin-  prick test response to 
soy, but only 1 (3%) had a clinical reaction to soy and another 
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gredient labels when purchasing prepackaged foods, inform 
the school authorities about the presence of allergy to peanuts, 
and develop an action plan to be implemented in the event 
of an allergic emergency. There are multiple reliable online 
resources for families and patients in need of further informa-
tion, some of which are included in Table 1. 
In the acute setting, patients and family members are ad-
vised to inject epinephrine early during the course of the re-
action as this has been shown not only to reduce the risk of 
a fatal outcome32 but also to reduce the likelihood of a bi-
phasic reaction.33 Asthma, especially when poorly controlled, 
is a recognized risk factor for near-  fatal or fatal anaphylaxis.34 
In individuals at risk for anaphylaxis, it is crucial to stress 
the need to ensure that asthma remains well controlled at all 
times. Patients and parents are always instructed to go to the 
nearest emergency department if they or their child develops a 
systemic reaction and / or need to use injectable   epinephrine.
Therapies under Investigation
Some therapeutic modalities are currently under investiga-
tion and show considerable promise. These include monoclo-
nal anti-  IgE, oral peanut desensitization and immunotherapy, 
Chinese herbal formulas, probiotics, and heat-  killed Listeria 
monocytogenes (HKL).
Anti-  IgE
Allergic reactions are mediated by   antigen-  specific IgE bound 
to high-  affinity receptors (FcεRI) on mast cells and baso-
phils.35 TNX-  901 is a humanized IgG1 monoclonal antibody 
against IgE that binds with high affinity to an epitope in the 
CH3 domain, masking a region responsible for binding to 
FcεRI. Leung and colleagues divided 84 patients with peanut 
allergy into four groups: a placebo arm and three active treat-
ment groups receiving either 150, 300, or 450 mg of TNX-
  901 subcutaneously every 4 weeks for four doses.36 Several 
and hazelnut paste, icing, glazes, marzipan, and nougat; artifi-
cial nuts (peanuts that have been altered to look and taste like 
almonds, pecans, and walnuts); baked goods (cakes, cookies, 
doughnuts, pastries); cereals; chili;   cross-  contamination (con-
tainers, foods deep fried in oil, utensils); desserts (frozen des-
serts, frozen yogurts, ice cream, sundae toppings); dried salad 
dressing, soup mix; ethnic foods (including sauces and soups); 
fried foods; gravy; hydrolyzed plant protein  /    vegetable protein; 
peanut oil; snack foods (candy, chocolate, dried fruits, energy /   
granola bars, mixed nuts, popcorn, potato chips, trail mixes); 
and vegetarian meat substitutes. Nonfood sources containing 
peanut protein include ant baits, bird feed, mouse traps, and 
pet food; cosmetics; sunscreens; craft materials; medications;   
vitamins;   mushroom-  growing medium; and stuffing in toys.28
Outgrowing Peanut Allergy
In comparison to allergy to milk and egg, it was tradition-
ally thought that allergy to peanut is rarely outgrown. How-
ever, one study has shown that peanut allergy can be out-
grown in as many as 21.5% of patients.29 In another study, 
patients with a history of peanut allergy could successfully 
pass their oral challenge with peanut according to their se-
rum   peanut-  specific IgE level. More specifically, 55% of chil-
dren with a   peanut-  specific IgE of 5 kUA /   L or less, 63% with 
a   peanut-  specific IgE of 2 kUA /   L or less, and 73% with an un-
detectable   peanut-  specific IgE passed an oral challenge with 
peanut.30 These data suggest that patients with a history of 
peanut allergy and a   peanut-  specific IgE level of 5 or less have 
at least a 50% chance of outgrowing their allergy. This infor-
mation, along with the details of previous clinical reactions 
and the results of ongoing allergic evaluation, can then be 
used to stratify current risk and prognosticate. Also, parents 
and patients need to know that there is a possibility of resen-
sitization after a negative prick skin test (PST) and negative 
challenge, especially in the absence of regular intake.31
Management
Management of peanut allergy is based mainly on
1.    Educating patients and families to avoid peanuts and 
  peanut-  containing products
2.    Awareness of early signs of an allergic reaction result-
ing from accidental exposure
3.    Education on the proper use of self-  injectable epineph-
rine (eg, Twinject or EpiPen autoinjectors)
Patients and caregivers of a child with peanut allergy, includ-
ing parents, teachers, babysitters, daycare workers, and other 
family members, must be instructed to carefully read all in-
Table 1. Online Resources for Families and Patients in Need of Further 
Information about Peanut Allergy
Name of Organization Website
Anaphylaxis Canada http: //   www  .anaphylaxis  .ca
Allergy Asthma Information 
Association
http: //   www  .aaia  .ca
The Food Allergy and Anaphylaxis 
Network
http: //   www  .foodallergy  .org
American College of Allergy, Asthma 
and Immunology
http: //   www  .acaai  .org
American Academy of Allergy, 
Asthma and Immunology
http: //   www  .acaai  .org
Food You Can Eat http: //   www  .foodyoucaneat  .com
Association Québécoise des Allergies 
Alimentaires 
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ducted a prospective study dividing newborn infants into two 
groups receiving either the probiotic Lactobacillus rhamnosus 
strain GG (ATCC 53103) or placebo.41 At 4 years of age, there 
was a significant decrease in the prevalence of atopic derma-
titis (AD) in the Lactobacillus treatment group, suggesting a 
role for probiotics in the prevention of the development of AD. 
However, the number of children with allergic rhinitis and 
asthma did not differ between the two groups, although the 
concentration of exhaled nitric oxide, considered a marker of 
bronchial inflammation, was significantly greater in children 
receiving placebo than in those receiving Lactobacillus. When 
added in vitro, probiotics resulted in enhanced production 
of IFN-  γ, interleukin (IL)-  10, and tumour necrosis factor α. 
However, oral administration of probiotics to children with 
food allergy, some of whom were allergic to peanut, is associ-
ated with a decrease in IgE production in vitro.41 This may   
support a role for probiotics in protecting against or amelio-
rating the allergy to peanut, although this is still experimental.
Heat-  Killed Listeria
HKL is a potent stimulator of the innate immune system. 
Yeung  and  colleagues  found  that  mice  immunized  with 
  keyhole-  limpet hemocyanin (KLH) mixed with HKL devel-
oped a reversion of the established immune responses domi-
nated by the production of Th2 cytokines and high levels of 
KLH-  specific IgE.42 Treatment with HKL induced a Th1-  type 
response with high levels of IFN-  γ and IgG2a and low KHL 
levels of IgE and IL-  4. These results suggest that use of HKL 
as an adjuvant during immunization can successfully bias the 
development of   antigen-  specific cytokine synthesis toward 
Th1 cytokine production even in the setting of an ongoing 
Th2-  dominated response. Frick and colleagues found KHL 
subcutaneous vaccination with peanut allergen and HKL in-
creased the threshold for peanut allergen–induced skin reac-
tions and symptoms in   peanut-  allergic dogs.43 Similar data 
have not yet been developed in humans, and the safety of this 
approach in human remains unclear.
Summary
Peanut allergy continues to be a major   health-  related issue 
worldwide, with many theories advanced to explain this ap-
parent rise in prevalence. Manifestations of peanut allergy 
may be life-  threatening and require an aggressive approach to 
risk factor modification and management, with emphasis on 
prevention and the early use of injectable epinephrine. Mul-
tiple novel therapeutic options are under investigation with 
considerable prospects for successful modification of a com-
mon, potentially fatal condition. 
weeks after completing the study, patients on the higher dose 
of anti-  IgE therapy had a significant increase in the thresh-
old of sensitivity to peanut by oral food challenge, from one 
peanut (178 mg) to almost nine peanuts (2,805 mg). Despite 
the short duration of the study, one would predict that indefi-
nite administration of anti-  IgE is needed to maintain a state 
of relative tolerance.
Immunotherapy and DNA Immunization
Oppenheimer and colleagues conducted a trial of rush injec-
tion immunotherapy for the treatment of anaphylactic sensi-
tivity to peanut.37 Patients in the treatment group were able 
to tolerate increased amounts of peanut in food challenges 
after treatment. Unfortunately, there was a high rate of ad-
verse systemic reactions, including a case of fatal anaphylaxis, 
associated with the treatment group compared with the group 
receiving placebo.
Another approach makes use of deoxyribonucleic acid 
(DNA)  immunization.  DNA  immunization  employs  the 
subcutaneous injection of a plasmid DNA vector encoding 
a specific allergenic protein. After uptake and processing by 
  antigen-  presenting cells, it is presented to T cells in the con-
text of the major histocompatibility complex. This approach is 
thought to induce a Th1 phenotypic response with upregula-
tion of interferon (IFN)-  γ, an increase in IgG2a, and suppres-
sion of   allergen-  specific IgE production.38 This approach has 
thus far been used in murine models and has yet to be applied 
to human subjects.
Chinese Herbal Formula
A  herbal  formula  called  Food  Allergy  Herbal  Formula 
  (FAHF)-  1 was previously reported to block systemic ana-
phylactic in mice sensitized to peanut protein. It does so 
by reducing mast cell degranulation and histamine release, 
  peanut-  specific serum IgE level, and Th2 cytokine secretion.39 
A subsequent report used a refined herbal formula,   FAHF-  2, 
produced after exclusion of two herbs from the original for-
mula.   Peanut-  sensitized mice pretreated with FAHF-  2 for 7 
weeks had no signs of anaphylaxis following peanut chal-
lenge 1, 3, and 5 weeks posttherapy. It was concluded that 
FAHF-  2 treatment protected against active anaphylaxis in 
  peanut-  allergic mice.40 However, this herbal formula has not 
yet been studied in humans for safety and efficacy.
Probiotics
Probiotics are bacterial components that enhance the host’s 
intestinal microbial balance. Kalliomaki and colleagues con-  Al-  Ahmed et al, Peanut Allergy  143
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